Overview

Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
Female
Summary
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving panitumumab and cisplatin together with pelvic radiation therapy may be effective in treating patients with cervical cancer. PURPOSE: This phase II trial is studying the side effects of giving panitumumab and cisplatin together with pelvic radiation therapy in treating patients with stage IB, stage II, or stage III cervical cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Medical University Innsbruck
Treatments:
Antibodies, Monoclonal
Cisplatin
Panitumumab
Criteria
DISEASE CHARACTERISTICS:

- Histologically confirmed cervical cancer, including the following subtypes:

- Squamous small-cell or large-cell carcinoma

- Adenosquamous cell carcinoma

- Adenocarcinoma

- Keratinizing or non-keratinizing carcinoma

- Stage IB-IIIB disease

- No para-aortic lymph node metastases or clinical indication for para-aortic field
irradiation

- No predominant and clinically effective neuroendocrine tumor cell differentiation

PATIENT CHARACTERISTICS:

- WH0 performance status 0-2

- Serum creatinine clearance > 50 mL/min

- No other prior or current malignancy within the past 5 years except adequately treated
nonmelanoma skin cancer or carcinoma in-situ of the cervix

- No acute life-threatening vaginal hemorrhage (requiring emergency irradiation or RBC
transfusion)

PRIOR CONCURRENT THERAPY:

- Not specified